Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals, Inc. - Common Stock (NQ:VRPX)

0.6695 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Virpax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Virpax Pharmaceuticals Announces Reverse Stock Split
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering
From Spartan Capital Securities, LLC
Via GlobeNewswire
News headline image
Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering
From Spartan Capital Securities, LLC
Via GlobeNewswire
News headline image
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
From Virpax Pharmaceuticals
Via Business Wire
News headline image
Virpax Regains Compliance with Nasdaq Minimum Bid Price
From Virpax Pharmaceuticals
Via Business Wire
News headline image
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
From Virpax Pharmaceuticals
Via Business Wire
News headline image
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
From Virpax Pharmaceuticals
Via Business Wire
News headline image
Virpax Announces Pricing of $2.25 Million Public Offering
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
From Virpax Pharmaceuticals
Via Business Wire
News headline image
Virpax Pharmaceuticals Reports 2023 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
From Virpax Pharmaceuticals
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.